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SUMMARY. Supraventricular tachycardia is the most common and clinically significant form of sustained fetal tachyar-
rhythmia in pregnancy; depending on duration and high rate variability heart failure and nonimmune hydrops may de-
velop which are associated with a high incidence of perinatal mortality. Doppler/echo diagnosis is usually accidental 
during second and third trimester of pregnancy. Therapeutic goals are cardioconversion to sinus rhythm and recovery of 
heart failure. We present a case of fetal supraventricualr tachycardia diagnosed at 29 weeks of gestation with nonimmune 
hydrops. Treatment with digoxin and amiodarone was successful. The heart rate restored to sinus rhythm and nonim-
mune hydrops resolved within three weeks of treatment. Therapy with two drugs that act synergistically may be more 
efficient than monotherapy in blocking likely atrio-ventricular reentry mechanism by accessory pathway in sustained 
supraventricular tachycardia, thus allowing resolution of hydrops with favorable management outcome.
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SA`ETAK. Supraventrikularna tahikardija je naj~e{}i i klini~ki najzna~ajniji oblik fetalne tahiaritmije u trudno}i, a ovi-
sno o trajanju i visini sr~ane aktivnosti mogu se razviti zatajenje srca i neimuni fetalni hidrops, oboje povezani s lo{im 
perinatalnim ishodom. Tijekom drugog i tre}eg tromjese~ja dijagnoza se ~esto slu~ajno postavlja ultrazvu~nim dopler-
skim nalazom. Terapijski cilj je konverzija u sinus ritam i oporavak sr~ane funkcije. Donosimo prikaz slu~aja fetalne 
supraventrikularne tahikardije s neimunim hidropsom, dijagnosticirane u 29. tjednu trudno}e. Terapija digoksinom i 
amiodaronom bila je uspje{na. Ponovo je uspostavljen sinusni ritam sr~ane frekvencije, a neimuni hidrops se povukao 
unutar tri tjedna lije~enja. Terapija dvama lijekovima sa sinergisti~kim djelovanjem mo`e biti u~inkovitija od monotera-
pije u blokiranju vjerojatno ponovnog ulaska atrio-ventrikularnog impulsa pomo}u sporednog puta u supraventrikular-
noj tahikardiji, time dopu{taju}i povla~enje hidropsa te bolji ishod.
Introduction
Supraventricular tachycardia is the most common and 
clinically significant form of sustained fetal tachyar-
rhythmia in pregnancy. Depending on duration and high 
rate variability, heart failure and nonimmune hydrops 
may develop, that are associated with a high incidence 
of perinatal mortality. Therapeutic goals are cardiocon-
version to sinus rhythm and recovery of heart failure, 
most frequently by digoxin and sotalol.
Case report
A 28 year old primigravida at 29 weeks of gestation 
(with ultrasound analysis the pregnancy was 2 weeks 
younger) was referred to our antenatal clinic because of 
fetal tachycardia detected during her routine antenatal 
scan. She was transferred from another clinical hospital 
where she was treated with sotalol on which she devel-
oped allergic reaction. Her antenatal period was une-
ventful till 26 weeks when Doppler/M-echocardiogra-
phy showed fetal supraventricular tachycardia (SVT) 
with minimal pericardial effusion. There was no history 
of fever or thyrotoxicosis. In family history, her mother 
has angina pectoris and arterial hypertension. The pa-
tient was admitted to our hospital for administration of 
antiarrhythmic therapy. At admission patient’s height 
was 168 cms and weight 73(+9) kg. Blood pressure was 
110/60 mmHg. ECG: sinus rhythm with 76 bpm.
Fetal echocardiography showed normal heart posi-
tion in left hemithorax with higher cardiothoracic index 
of 0.42 (normal 0.25–0.35), enlarged heart silhouette 
underlying both dilated atria with normal ventricles and 
valvular morphology, normal atrioventricular concord-
ance and relations to surrounding internal organs. Pul-
monary veins and vv.cavae were of normal anatomy and 
inflow. Patent foramen ovale with r-l shunt and ductus 
Botalli with communications between pulmonary artery 
and aorta corresponded with the mildly decreased same 
pressures in both pulmonal artery and aorta of 0.4m/s 
(normal 0.6–07m/s). Doppler/M-mode echocardiogra-
phy demonstrated paroxysms of SVT in the range of 
237–260 beats per minute intermittently falling down to 
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131 beats per minute, but only rare and transitory. There 
were no signs of hydrops.
The patient was started on digoxin 3×0.5 mg i.v. per 
day for three days and continued 3×0.5 mg per os daily. 
During complete treatment, serum electrolytes and elec-
trocardiography were monitored. Three days after ini-
tial therapy with digoxin the patient developed symp-
toms of digoxin toxicity with epigastric pain, vomiting 
and nausea and ECG–changes showed intermittent first 
degree and second degree Mobitz II AV block and ST 
denivelation. Serum digoxin levels were elevated up to 
5.3 mmol/L (normal 0.7–2.5 mmol/L). Fetal heart rate 
was found to be normal. She stopped taking digoxin 
three days till clinical and ECG normalization and after 
that she again continued digoxin treatment in dose 3×0.5 
mg per os daily with expected maintenance dose (serum 
range 2.0–2.5 mmol/L). Fetal heart rate was found to be 
between 214–129/min with prevalence of tachycardia. 
Two weeks later Doppler/M-echocardiography showed 
the signs of fetal hydrops, the most probable because of 
underlying heart decompensation. As there were no 
signs of maternal digoxin intoxication and fetal heart 
rate was still high and unstable, amiodarone in a dose of 
3×200 mgs was added as second line therapy. The dose 
of digoxin was reduced to 2×0.10 mg per day and amio-
darone, after one week of therapy was gradually reduced 
to 2×200 mg per day without any adverse effects. Fetal 
cardiac decompensation and fetal hydrops disappeared 
three weeks after starting antiarrhythmic drugs. The fe-
tal heart rate remained stable at 120–140 bpm till deliv-
ery with only a few exacerbations. Last fetal ultrasound 
showed breech presentation. Patient’s autoimmune 
workup and TORCH screening were negative. Her thy-
roid function tests were normal.
At 38 week and 6 days of gestation (on ultrasound 
36+6 weeks) she underwent elective cesarean section. 
The 2920 gs male infant with Apgar score 10/10 was 
delivered. The baby boy was transferred to Clinic of ne-
onatology for further observation. On second day of 
hospitalization, the baby boy developed RDS, which 
was treated with oxygen and i.v. antibiotics with gradu-
al respiratory improvement. During hospitalization ba-
by’s heart was monitored and was treated with digoxin 
postnatally.
Discussion
Cardiac arrhythmias develop from impairment of im-
pulse generation, impulse conduction or both. It is, 
however, difficult to establish the exact mechanism for 
many clinical arrhythmias that can appear as response 
to ischemia, inflammation, electrolyte disturbances, al-
tered load states, structural heart defects, inherited ge-
netic conditions and other causes.1 Approximately 1% 
of all pregnancies are complicated by a fetal arrhyth-
mia. Although, in most of the cases they are benign and 
of short duration, 1–3 % is complicated and can lead to 
fetal death.2
There are three different types of fetal arrhythmias 
that can be seen in pregnancy such as fetal tachycardia 
with baseline fetal heart rate over 160/min (SVT, atrial 
flutter or fibrillation, ventricular tachycardia), fetal bra-
dycardia with baseline heart rate less than 110/min., 
and the most common, premature beats as atrial and 
ventricular extrasystoles. An initiating premature beat 
caused by abnormal automaticity can precipitate an epi-
sode of SVT sustained by AV reentry mechanism and 
accessory pathway with AV conduction 1:1 up to 220 to 
260 bpm (accounts for 93% of total SVT with 1:1 AV 
conduction).3,4 It is the most commonly encountered fe-
tal cardiac arrhythmia in pregnancy that may be associ-
ated with adverse perinatal outcome if untreated.5 Fetal 
SVT can be presented like non sustained (tachycardia 
with intermittent sinus rhythm) and sustained (pro-
longed uninterrupted tachycardia of >12h), which is he-
modynamically more dangerous for fetal life.4 In this 
case, sustained SVT with 1:1 atrioventricular conduc-
tion was diagnosed prenatally by the presence of 1:1 
atrioventricular contraction sequence during tachycar-
dia, abrupt onset and terminations with minimal heart 
rate variability. Our patient was without favorite risk 
factors for development of arrhythmia like smoking, 
caffeine and illicit drugs. Fetal Doppler/M-echocardi-
ography showed structurally normal heart with only 
mildly enlarged cardiac silhouette and both atria.
In addition, there are some newer methods used today 
for the diagnosis of SVT such as magnetocardiogram 
(MCG) and Doppler myocardial deformation analy-
sis.6,7
The prognosis and treatment of this kind of arrhyth-
mia depend on the presence or absence of fetal hemody-
namic compromise, gestational age of fetus at which the 
tachycardia occurs, the ventricular rate, the percentage 
of the time that the tachycardia is present and the site of 
origin of the tachycardia.5,8 Spontaneous resolution of 
SVT has been reported in some cases to occur in utero 
or later, during neonatal period.9,10 In fetus with a nor-
mal anatomical survey, the management depends upon 
the gestational age and the presence or absence of hy-
drops. In our case we demonstrated nonimmune hy-
drops fetalis secondary to sustained SVT that appeared 
2 weeks after its initiation to develop heart failure from 
multiple episodes of tachycardia and recurring at rela-
tively »slow heart rates«.5,11
The most important goal of treatment is the preven-
tion or resolution of hemodynamic compromise. Today, 
numerous antiarrhythmic drugs have been prescribed 
for the treatment of fetal tachycardia as digoxin, sotalol, 
amiodarone and flecainide. We began the treatment 
transplacentally with digoxin which is the drug of first 
choice for the treatment of SVT and two weeks later in 
the sense of developing hydrops phenomenon, we in-
cluded in the treatment additionally oral amiodarone, 
preserving myocardial contractility, because the treat-
ment and prognosis of SVT depends not only of sup-
pression rate of SVT but recovery from fetal congestive 
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heart failure and hydrops as well.12 Digoxin is cardiac 
glycoside and for a long time prominent drug in the 
therapy of congestive heart failure. It has positive ino-
tropic and negative chronotropic properties that increase 
cardiac output and decrease heart rate. With these char-
acteristics, digoxin prolongs the refractoriness of the 
AV node and terminates the circular movements within 
re-entrant circuit so that aberrant wave of excitation 
reaches depolarized tissue.5 Digoxin is effective and 
nontoxic in relatively narrow serum range (0.8 – 2.0 ng/
mL), so the optimum therapy for pregnant women or 
fetus requires an accurate measurement of serum dig-
oxin levels.13 During pregnancy increased digoxin dos-
age may be necessary because of enhanced renal clear-
ance and expanded blood volume. Reported fetal : ma-
ternal (F:M) plasma concentration ratios vary from 0.4 
to 0.9.14,15 However, in case of fetal hydrops, this ratio is 
reduced because the placental transfer of the digoxin is 
limited. In addition, conversion to sinus rhythm with di-
goxin is achieved in 50% of nonhydropic fetuses and 
only in 15–25% in hydropic fetuses.5,16,17 Hence, medi-
cation with good placental transfer, such as amiodarone, 
should be used from the beginning of fetal treatment for 
hydrops. Digoxin has a few maternal side effects which 
are related to overdosing like nausea, vomiting and 
headache.4 There also can be found maternal cardiac ad-
verse effects such as ventricular extrasystoles or heart 
block that was seen in our case.
Because of low conversion rate with digoxin, second 
line drugs are frequently required to achieve sinus 
rhythm as it was in our case with inclusion of amiodar-
one in therapy.
Amiodarone prolongs the repolarization of the myo-
cardium. A large study by Strasburger et al.18 was pub-
lished in which amiodarone had a 93% successful rate 
of conversion as second line therapy in fetal SVT tachy-
cardia complicated with hydrops. Treatment with amio-
darone has been associated with transient biochemical 
neonate hypothyroidism, maternal photosensitive skin 
rash and thrombocytopenia. In addition, amiodarone is 
a suitable second line treatment in hydropic SVT and 
because of unsignificant possibility of proarrhythmic 
events in distinction of flecainide and sotalol. Amiodar-
one administration has been found to increase the 
steady-state digoxin concentration, and maintenance 
doses of digoxin should be decreased by ≥50%.19
There is also a question whether to treat prenatally or 
postnatally. The decision mainly depends on gestational 
age and in early gestational weeks prenatal treatment is 
the reasonable management. However, if hydrops does 
not resolve in 2 weeks, postnatally treatment is recom-
mended.2 Transplacental therapy is proper mode of 
therapy in nonhydropic fetuses and first choice in hy-
dropic fetuses. But, when conversion to sinus rhythm is 
not achieved, direct fetal therapy should be recom-
mended.
After successful fetal rhythm conversion, dosage is 
maintained till delivery. If the heart rate is controlled, 
vaginal delivery is recommended and newborns are 
treated for at least 6–12 months.9 In the case of cesarean 
section, the maturity of fetal lungs must be verified to 
avoid neonatal adverse affects. One third or more ne-
onates postnatally will be free of further SVT probably 
due to involution of the abnormal pathway.
Conclusion
Sustained fetal SVT with instability rates of ventricu-
lar rhythm and prolonged duration can be serious condi-
tion in which the fetus is at significant risk for develop-
ing congestive heart failure and hydrops, neurological 
damage and intrauterine death. Vigilant fetal heart rate 
control and ultrasound monitoring as well as adequate 
selection of antiarrhythmic drugs are crucial in tachyar-
rhythmia suppression and hydrops resolution. Digoxin 
and oral amiodarone with its favorable effect on myo-
cardial contractility and well known amiodarone high 
conversion rate in fetal SVT complicated by hydrops 
were proper option in terms of management outcome.
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U ^ASOPISU »GYNAECOLOGIA ET PERINATOLOGIA«
OBJAVLJENE PREPORUKE (SMJERNICE)
HRVATSKOG DRU[TVA ZA PERINATALNU MEDICINU HLZ-a
 1) Novoro|en~e s mekonijskom plodovom vodom (str. 181/2008).
 2) Primjena prostaglandina u novoro|en~adi sa sr~anom gre{kom (str. 182/2008).
 3) Smjernice za prerano prijevremeno prsnu}e vodenjaka (str. 132/2009).
 4) Europske smjernice za lije~enje neonatalnog sindroma respiratornog distresa (str. 140/2009).
 5) Novoro|ena~ki RDS (str. 160/2009).
 6) Antibiotska profi laksa rane neonatalne sepse uzrokovane beta hemoliti~kim streptokom grupe B (str. 119/2010).
 7) Prijete}i prijevremeni porod (str. 121/2010).
 8) Trudno}a/porod nakon ranijega carskog reza (str. 123/2010).
 9) Prenatalni probir i dijagnostika kromosomopatija (str. 125/2010).
10) Antenatalni »in utero« transport djeteta (str. 54/2011).
